Lexaria Bioscience Corp. (Nasdaq: LEXX), (the “Firm” or “Lexaria”), a worldwide innovator in drug supply platforms, is happy to announce the engagement of the contract analysis group (“CRO”) to execute and report on its 2026 animal Examine #1 (GLP-1-A26-1) that can consider various formulation enhancements utilizing each DehydraTECH-semaglutide (“DHT-sema”) glucagon-like peptide-1 (“GLP-1”) compositions and DehydraTECH-CBD (“DHT-CBD”) compositions to discover the potential for added improved efficiency in addition to stake new mental property (“IP”) claims (the “Examine”).
Contracts with the CRO have been signed, supplies sourcing is underway, and Examine design is being finalized with the purpose of starting dosing inside roughly 60 days.
“The worldwide arms race in diabetes management, weight reduction and different GLP-1-indicated areas of therapy is intensifying with latest new oral medicine being authorised by the Meals and Drug Administration (“FDA”),” mentioned Richard Christoper, CEO of Lexaria Bioscience. “With tens of billions of {dollars} in new annual income quickly anticipated within the sector, there has by no means been a greater time to stake new authorized IP claims with a view to provide the pharmaceutical business improved efficiency together with lowering unwanted effects, whereas enhancing Lexaria’s chances of changing into an indispensable supplier of improved drug supply expertise.”
Whereas ultimate design parameters of this Examine are ongoing, it’s anticipated to make the most of Sprague-Dawley rats with 8 to 11 separate arms evaluating various completely different novel compositions. Blood samples might be taken at a number of timepoints by means of an 8-24-hour post-dosing interval to quantify the pharmacokinetic efficiency of every composition. As well as, the Examine may also measure drug concentrations within the mind since DehydraTECH has, up to now, evidenced obvious superior absorption of energetic elements into mind tissue, an space of intense curiosity as a result of the truth that GLP-1 drug efficiency is more and more understood to incorporate and even rely on involvement of mind neurochemistry, thus making mind biodistribution important. There might be one reference arm utilizing an present DHT-sema composition and one other reference arm utilizing an present DHT-CBD composition. Lexaria intends to leverage the wealth of examine knowledge that we’ve got amassed from earlier work by using our proprietary historic knowledge and the reference arms as baseline comparators to the present Examine outcomes as we seek for areas of superiority.
One of many novel aims of this Examine might be to guage different/additive formulations to SNAC (salcaprozate sodium) which is at present in use by Novo Nordisk® with their oral Rybelsus® and Wegovy® pill merchandise. If Lexaria is ready to set up novel new formulations with superiority to SNAC, we could possibly register new patents and create priceless new proprietary IP and an business different to SNAC that may very well be of curiosity throughout the keenly aggressive GLP-1 sector.
Lexaria will replace its stakeholders as soon as dosing has begun. The Examine is absolutely funded from present company sources.
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria’s patented drug supply formulation and processing platform expertise which improves the best way all kinds of medicine enter the bloodstream, at all times by means of oral supply. DehydraTECH has repeatedly evidenced the power to extend bio-absorption, cut back side-effects, and ship some medicine extra successfully throughout the blood mind barrier. Lexaria operates a licensed in-house analysis laboratory and holds a strong mental property portfolio with 65 patents granted and extra patents pending worldwide. For extra data, please go to www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press launch contains forward-looking statements. Statements as such time period is outlined below relevant securities legal guidelines. These statements could also be recognized by phrases equivalent to “anticipate,” “if,” “imagine,” “plan,” “estimate,” “count on,” “intend,” “might,” “might,” “ought to,” “will,” and different related expressions. Such forward-looking statements on this press launch embrace, however should not restricted to, statements by the Firm referring to the meant use of proceeds from the providing and referring to the Firm’s means to hold out analysis initiatives, obtain regulatory approvals or grants or expertise constructive results or outcomes from any analysis or examine. Such forward-looking statements are estimates reflecting the Firm’s finest judgment primarily based upon present data and contain various dangers and uncertainties, and there might be no assurance that the Firm will really obtain the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you shouldn’t place undue reliance on these forward-looking statements. Elements which might trigger precise outcomes to vary materially from these estimated by the Firm embrace, however should not restricted to, market and different circumstances, authorities regulation and regulatory approvals, managing and sustaining progress, the impact of opposed publicity, litigation, competitors, scientific discovery, the patent software and approval course of, potential opposed results arising from the testing or use of merchandise using the DehydraTECH expertise, the Firm’s means to take care of present collaborations and understand the advantages thereof, delays or cancellations of deliberate R&D that might happen associated to pandemics or for different causes, and different elements which can be recognized every so often within the Firm’s public bulletins and periodic filings with the US Securities and Trade Fee on EDGAR. The Firm gives hyperlinks to third-party web sites solely as a courtesy to readers and disclaims any duty for the thoroughness, accuracy or timeliness of knowledge at third-party web sites. There isn’t any assurance that any of Lexaria’s postulated makes use of, advantages, or benefits for the patented and patent-pending expertise will in actual fact be realized in any method or in any half. No assertion herein has been evaluated by the Meals and Drug Administration (FDA). Lexaria-associated merchandise should not meant to diagnose, deal with, treatment or stop any illness. Any forward-looking statements contained on this launch communicate solely as of the date hereof, and the Firm expressly disclaims any obligation to replace any forward-looking statements or hyperlinks to third-party web sites contained herein, whether or not on account of any new data, future occasions, modified circumstances or in any other case, besides as in any other case required by legislation.
INVESTOR CONTACT:
George Jurcic – Head of Investor Relations
ir@lexariabioscience.com
Telephone: 250-765-6424, ext 202
